News

manilatimes4d
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ...
Morningstar4d
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...
BioSpace4d
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...